Medical Oncologist
Targeted therapy for GIST
GIST Treatment: — Why This Cancer Changed Targeted Therapy Forever
GIST — gastrointestinal stromal tumour — is where doctors first proved that matching a specific drug to a specific gene mutation could change what was possible in cancer treatment. Almost every GIST is driven by a detectable mutation, and your oncologist will identify it before treatment starts.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Mutation first, drug second — Your oncologist tests the tumour tissue before choosing a drug. The specific mutation — not just the diagnosis — determines which treatment is right for you.
- Most GISTs have KIT mutations — KIT mutations are found in the majority of GISTs, and most respond to the first targeted drug approved for this cancer.
- Some mutations need different drugs — The PDGFRA D842V variant did not respond to the original drug. A newer drug approved specifically for that mutation changed outcomes for that group.
- Wild-type GIST is different — A minority of GISTs have no KIT or PDGFRA mutation. These need a separate workup and often a specialist multidisciplinary discussion.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
GIST is a rare stomach and bowel tumour driven by gene mutations that targeted drugs can specifically block. Most GISTs carry KIT mutations; a smaller number carry PDGFRA mutations. Your mutation type — identified from your biopsy — determines which drug you receive, which is why testing comes before treatment.
What is GIST and why does it respond to targeted therapy?
GIST stands for gastrointestinal stromal tumour — a rare cancer arising from the connective tissue of the stomach, small bowel, or, less often, elsewhere in the abdomen.
Almost all GISTs are driven by a permanently switched-on protein, the result of a mutation in the KIT or PDGFRA gene. Targeted drugs work by blocking that specific protein and interrupting the signal that keeps cancer cells dividing.
In 2001, early results with imatinib in GIST showed a level of response that had not been seen in this cancer before. That success became the founding evidence for precision oncology — the principle that identifying a tumour's molecular driver and blocking it directly is more effective than treating every cancer the same way.
Which gene mutations are tested before GIST treatment starts?
Testing is done on your tumour tissue, usually from the biopsy already taken at diagnosis. Your oncologist looks for mutations in the KIT gene first, then the PDGFRA gene if KIT is negative.
KIT mutations are found in the majority of GISTs. The specific location within the gene — called an exon — matters for treatment. Exon 11 mutations are the most common and respond well to imatinib. Exon 9 mutations are less common and may need a different approach, which your oncologist will discuss.
PDGFRA mutations are found in a smaller proportion of GISTs. The most clinically important PDGFRA variant is D842V, which did not respond to imatinib and requires a different drug. Other PDGFRA variants generally do respond to imatinib.
GISTs with no detectable KIT or PDGFRA mutation are called wild-type. This group is a minority and may be driven by different alterations — including changes in SDH or NF1 genes — which require separate investigation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How is GIST treatment decided after diagnosis?
Tissue biopsy
A sample of the tumour is taken and sent to the laboratory. This confirms the diagnosis and provides material for mutation testing.
Mutation testing
The laboratory analyses the biopsy for KIT and PDGFRA mutations and identifies the specific exon or variant. This result shapes every treatment decision that follows.
Staging scans
CT or PET-CT imaging establishes whether the tumour is localised or has spread, and whether surgery is possible.
Multidisciplinary review
Your case is discussed by a team including a medical oncologist, surgeon and radiologist. The mutation result, staging and your overall health are considered together.
Treatment starts
For most patients with advanced or high-risk GIST, targeted therapy begins before or after surgery, or instead of surgery where that is not possible.
Ongoing monitoring
Imaging and blood tests are repeated at intervals to check whether the cancer is responding. Treatment is reviewed and changed if it stops working.
What do the terms in your GIST report mean?
- KIT (also called CD117)
- A gene that produces a protein driving cell growth. In most GISTs, a mutation keeps this protein permanently active. Targeted drugs block it.
- PDGFRA
- A related gene that can carry mutations driving a minority of GISTs. The specific variant — particularly D842V — determines which drug is appropriate.
- Exon
- A section of a gene. In KIT, the exon where the mutation sits — most often exon 9 or 11 — affects which drug works best and sometimes what dose is appropriate.
- Wild-type GIST
- A GIST with no detectable KIT or PDGFRA mutation. This group may be driven by SDH, NF1 or other gene alterations and needs separate investigation.
- Tyrosine kinase inhibitor (TKI)
- The class of drug to which imatinib, sunitinib, regorafenib, ripretinib and avapritinib all belong. They work by blocking the enzyme activity of mutant proteins.
- Adjuvant therapy
- Treatment given after surgery to reduce the risk of the cancer returning. In GIST, targeted therapy after surgery is standard for tumours assessed as high-risk.
Which drug is used for which GIST mutation?
KIT exon 11 mutation — the most common type
Imatinib is the standard first-line treatment for KIT exon 11 GIST and has been for over two decades. Response rates reported by NCCN and ASCO for this mutation type are among the highest seen with any targeted therapy in oncology. Treatment continues as long as the cancer is responding and side effects are acceptable. Most people with advanced GIST and an exon 11 mutation start here.
KIT exon 9 mutation
Imatinib is also used as first-line treatment, though NCCN guidance notes that exon 9 mutations may behave differently from exon 11 and that dose requires individual discussion with your oncologist. If imatinib stops working, sunitinib is the established second-line option recognised by NCCN for this group.
PDGFRA D842V mutation
This variant was largely resistant to imatinib, leaving patients in this group without an effective systemic option for many years. Avapritinib was developed specifically for PDGFRA D842V GIST and is recommended by NCCN as the preferred treatment for this mutation. If you have been told you have a PDGFRA mutation, confirming whether it is D842V matters — it changes which drug is appropriate.
Other PDGFRA mutations
Most PDGFRA variants other than D842V respond to imatinib, and imatinib is the general first-line choice for this group. Your oncologist will interpret your full mutation report to confirm this. The specific exon involved within PDGFRA is noted in your report and should be discussed with your treating team alongside the broader treatment plan.
Wild-type GIST (no KIT or PDGFRA mutation found)
There is no single standard drug for wild-type GIST. Management depends on identifying what is driving the tumour — SDH-deficient GISTs, NF1-associated GISTs and others each have different implications for treatment and follow-up. These cases are usually discussed at specialist multidisciplinary tumour boards. We do not yet have approved targeted drugs specifically indicated for all wild-type subtypes, and honest guidance requires saying so.
When the current drug stops working — what comes next
When imatinib stops controlling the cancer, sunitinib is the standard second-line option according to NCCN guidance. Regorafenib is recognised as a third-line option, and ripretinib is available in later lines. The sequence matters, and your oncologist will discuss what the evidence supports at each stage. Repeat tumour testing at progression can sometimes identify resistance mutations that inform which drug is most likely to help next.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Do I need a new biopsy before targeted therapy can start?
Usually not. Mutation testing is done on the tissue already collected when your GIST was diagnosed. A new biopsy may be needed only if the original sample was too small for testing, if the cancer has returned after treatment, or if there is a question about whether the tumour's biology has changed over time. Your oncologist will tell you whether the existing tissue is sufficient.
What is the aim of targeted therapy in GIST?
For localised GIST removed by surgery, targeted therapy given afterwards aims to reduce the risk of the cancer returning — it does not guarantee it will not. For advanced GIST, the aim is long-term control of the disease. In a proportion of patients that control can last for many years. What is achievable in your situation depends on your mutation type, the extent of disease and how you respond to treatment — a question your oncologist can answer in the context of your specific results.
How long do you take the targeted drug for in GIST?
For advanced GIST, treatment continues as long as it is working and side effects are manageable — this can be for years. Stopping imatinib in a patient with advanced GIST who is responding has consistently led to the cancer returning in studies, which is why indefinite treatment is the standard approach. For GIST treated with surgery, adjuvant imatinib is given for a defined period based on the risk assessment of your tumour, which your oncologist will explain.
What happens if imatinib stops working?
If your cancer starts growing on imatinib, your oncologist will confirm on imaging that the change is real before switching treatment. The next step is usually sunitinib, which NCCN recognises as the standard second-line treatment. After sunitinib, regorafenib and ripretinib are options at later lines. In some cases, re-testing the tumour to look for resistance mutations can inform which drug is most likely to help next.
Is GIST targeted therapy given as an inpatient stay?
No. GIST targeted drugs are all taken as tablets or capsules at home — you do not need to be admitted to hospital for the treatment itself. You will have regular outpatient visits for blood tests and imaging to monitor how the cancer is responding. At CION centres, ongoing monitoring is managed through day care and outpatient appointments, with imaging coordinated through partner centres as needed.
Should I get a second opinion on my GIST mutation report?
It is entirely reasonable to ask, particularly if you have been told you have wild-type GIST or an unusual mutation, if the mutation result is described as borderline, or if the treatment proposed seems different from what you have read about. Ask for your mutation report in writing. A specialist GIST team or a gastrointestinal oncology multidisciplinary meeting with experience in rare tumours is the right place for a second interpretation.